Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRV-TV is a live attenuated, oral, tetravalent bovine-human reassortant rotavirus vaccine developed by Shantha Biotechnics (a subsidiary of Sanofi Pasteur). The vaccine is engineered using technology from the US National Institutes of Health (NIH), utilizing the UK Compton strain of bovine rotavirus as a backbone to express human rotavirus VP7 serotypes G1, G2, G3, and G4. It is designed to prevent rotavirus gastroenteritis in infants and is typically administered as a three-dose oral series at 6-8, 10-12, and 14-16 weeks of age. Clinical development has progressed through Phase III trials in India, demonstrating safety and immunogenicity against the leading causes of severe childhood diarrhea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BRV-TV.